BETHLEHEM, Pa., April 23, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Eilaf Pharma S.A.E. will serve as exclusive distributor of Saladax’s My5-FU diagnostic test, which measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients, in Egypt and throughout the Middle East North African (MENA) region.
“Over the past year, we’ve been able to successfully expand our distribution of My5-FU in multiple markets worldwide creating new sales channels in more than a dozen countries,” said Adrienne Choma, Esq., Sr. VP and chief marketing officer of Saladax. “We’re happy to be working with Eilaf to provide patients with colorectal cancer in the region a new option to help maximize the therapeutic effect of their chemotherapy.”
My5-FU enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects. My5-FU is the first of Saladax’s innovative dose management tests commercially available.
Haytham Abuelfadl, M.D., MIBA, Eilaf’s Managing Director, said, “We’re delighted to be offering Saladax’s unique diagnostic test in Egypt and the other markets in our region. We hope that with this tool, our oncologists will be able to provide their patients with the most appropriate course of chemotherapy possible.” Eilaf is a new joint stock health care company that promotes products to market- leading positions in Egypt and the MENA region.
About My5-FU
Saladax’s first commercially available test for innovative dose management; My5-FU measures levels of 5-fluorouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.
About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company’s dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life. The Company’s 15 MyCareTM dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology. The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU). This assay is sold in the European Union by Saladax and its distribution partners as a CE-marked product and will be distributed in Japan by FALCO biosystems. In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds. For more information, visit www.saladax.com.
My5-FU is a registered trademark of Saladax Biomedical, Inc.
OnDose is a registered trademark of Myriad Genetics, Inc.
About Eilaf Pharma S.A.E.
Eilaf was founded in 2008 to represent dynamic companies from the USA and EU in Egypt and MENA region. Eilaf seeks to commercialize proprietary prescriptions, promote innovative devices and provide contract research services in key therapeutic areas. The company has two offices; one in Egypt & another in Saudi Arabia. Eilaf offers strong capabilities within the health care industry, including fast market accessibility and the delivery of new products to market. Eilaf is an ideal partner for companies seeking assistance in the development and commercialization of innovative applications across the MENA region.
Saladax Biomedical, Inc.
Adrienne Choma, Esq.
Sr. VP & Chief Marketing Officer
achoma@saladax.com
Eilaf Pharma S.A.E.
Haytham Abuelfadl, M.D., MIBA
Managing Director
h.abuelfadl@eilaf.info
Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com
SOURCE Saladax Biomedical, Inc.
